Cargando…

Difference in the Source of Anti-AQP4-IgG and Anti-MOG-IgG Antibodies in CSF in Patients With Neuromyelitis Optica Spectrum Disorder

OBJECTIVE: To elucidate the differences in the source and in the level of intrathecal synthesis between anti–aquaporin-4 antibodies (AQP4-IgG) and anti-myelin oligodendrocyte glycoprotein antibodies (MOG-IgG). METHODS: Thirty-eight patients with MOG-IgG–associated disease and 36 with AQP4-IgG–positi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Akaishi, Tetsuya, Takahashi, Toshiyuki, Misu, Tatsuro, Kaneko, Kimihiko, Takai, Yoshiki, Nishiyama, Shuhei, Ogawa, Ryo, Fujimori, Juichi, Ishii, Tadashi, Aoki, Masashi, Fujihara, Kazuo, Nakashima, Ichiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8312856/ https://www.ncbi.nlm.nih.gov/pubmed/33980704 http://dx.doi.org/10.1212/WNL.0000000000012175

Ejemplares similares

Pain in AQP4-IgG-positive and MOG-IgG-positive neuromyelitis optica spectrum disorders
por: Asseyer, Susanna, et al.
Publicado: (2018)

CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications
por: Kaneko, Kimihiko, et al.
Publicado: (2018)

Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders
por: Palace, Jacqueline, et al.
Publicado: (2019)

Differences in Advanced Magnetic Resonance Imaging in MOG-IgG and AQP4-IgG Seropositive Neuromyelitis Optica Spectrum Disorders: A Comparative Study
por: Schmidt, Felix A., et al.
Publicado: (2020)

Neuromyelitis optica MOG-IgG causes reversible lesions in mouse brain
por: Saadoun, Samira, et al.
Publicado: (2014)

Altered fovea in AQP4-IgG–seropositive neuromyelitis optica spectrum disorders
por: Motamedi, Seyedamirhosein, et al.
Publicado: (2020)

Rapid Administration of High-Dose Intravenous Methylprednisolone Improves Visual Outcomes After Optic Neuritis in Patients With AQP4-IgG-Positive NMOSD
por: Akaishi, Tetsuya, et al.
Publicado: (2020)

HLA association in MOG-IgG– and AQP4-IgG–related disorders of the CNS in the Dutch population
por: Bruijstens, Arlette L., et al.
Publicado: (2020)

Peripapillary hyper-reflective ovoid mass-like structures (PHOMS) in AQP4-IgG-positive neuromyelitis optica spectrum disease (NMOSD) and MOG-IgG-associated disease (MOGAD)
por: Gernert, Jonathan A., et al.
Publicado: (2022)

Cytoprotective IgG antibodies in sera from a subset of patients with AQP4-IgG seropositive neuromyelitis optica spectrum disorder
por: Tradtrantip, Lukmanee, et al.
Publicado: (2021)

Complement-dependent bystander injury to neurons in AQP4-IgG seropositive neuromyelitis optica
por: Duan, Tianjiao, et al.
Publicado: (2018)

MOG-IgG-Associated Optic Neuritis, Encephalitis, and Myelitis: Lessons Learned From Neuromyelitis Optica Spectrum Disorder
por: dos Passos, Giordani Rodrigues, et al.
Publicado: (2018)

Longitudinal Evaluation of Serum MOG-IgG and AQP4-IgG Antibodies in NMOSD by a Semiquantitative Ratiometric Method
por: Bollo, Luca, et al.
Publicado: (2021)

Epitope Analysis of Cerebrospinal Fluid IgG in Japanese Multiple Sclerosis Patients Using Phage Display Method
por: Fujimori, Juichi, et al.
Publicado: (2011)

NMO-IgG: A Specific Biomarker for Neuromyelitis Optica
por: Weinshenker, Brian G., et al.
Publicado: (2006)

Comparison of spontaneous brain activity revealed by regional homogeneity in AQP4-IgG neuromyelitis optica-optic neuritis versus MOG-IgG optic neuritis patients: a resting-state functional MRI study
por: Wang, Junqing, et al.
Publicado: (2017)

Intrastriatal injection of interleukin-1 beta triggers the formation of neuromyelitis optica-like lesions in NMO-IgG seropositive rats
por: Kitic, Maja, et al.
Publicado: (2013)

CD55 upregulation in astrocytes by statins as potential therapy for AQP4-IgG seropositive neuromyelitis optica
por: Tradtrantip, Lukmanee, et al.
Publicado: (2019)

Dramatic efficacy of ofatumumab in refractory pediatric-onset AQP4-IgG neuromyelitis optica spectrum disorder
por: Maillart, Elisabeth, et al.
Publicado: (2020)

Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG–Associated Disease and Neuromyelitis Optica Spectrum Disorders
por: Ringelstein, Marius, et al.
Publicado: (2021)

Plasmablasts as Migratory IgG-Producing Cells in the Pathogenesis of Neuromyelitis Optica
por: Chihara, Norio, et al.
Publicado: (2013)

Effects of neuromyelitis optica–IgG at the blood–brain barrier in vitro
por: Takeshita, Yukio, et al.
Publicado: (2016)

Anti Myelin Oligodendrocyte Glycoprotein associated Immunoglobulin G (AntiMOG-IgG)-associated Neuromyelitis Optica Spectrum Disorder with Persistent Disease Activity and Residual Cognitive Impairment
por: Pandit, Lekha, et al.
Publicado: (2017)

MOG-IgG- versus AQP4-IgG-Positive Optic Neuritis in Thailand: Clinical Characteristics and Long-Term Visual Outcomes Comparison
por: Narongkhananukul, Chanomporn, et al.
Publicado: (2020)

Incidence of AQP4-IgG seropositive neuromyelitis optica spectrum disorders in the Netherlands: About one in a million
por: Daniëlle van Pelt, E, et al.
Publicado: (2016)

Safety and efficacy of plasma exchange treatment in children with AQP4-IgG positive neuromyelitis optica spectrum disorder
por: Li, Zhichao, et al.
Publicado: (2023)

MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients
por: Pache, Florence, et al.
Publicado: (2016)

Retinal Nerve Fiber Layer May Be Better Preserved in MOG-IgG versus AQP4-IgG Optic Neuritis: A Cohort Study
por: Stiebel-Kalish, Hadas, et al.
Publicado: (2017)

Long-term Efficacy of Satralizumab in AQP4-IgG–Seropositive Neuromyelitis Optica Spectrum Disorder From SAkuraSky and SAkuraStar
por: Kleiter, Ingo, et al.
Publicado: (2022)

Neuromyelitis optica-IgG testing in an Indian cohort with neuromyelitis optica and related demyelinating disorders: Our experience
por: Unni, Narayanan, et al.
Publicado: (2013)

A multi-facet comparative analysis of neuromyelitis optica spectrum disorders in patients with seropositive and seronegative AQP4-IgG
por: Wang, Xiaojuan, et al.
Publicado: (2018)

Complement-independent bystander injury in AQP4-IgG seropositive neuromyelitis optica produced by antibody-dependent cellular cytotoxicity
por: Duan, Tianjiao, et al.
Publicado: (2019)

Astrocytic outer retinal layer thinning is not a feature in AQP4-IgG seropositive neuromyelitis optica spectrum disorders
por: Lu, Angelo, et al.
Publicado: (2022)

AQP4-IgG autoimmunity in Japan and Germany: Differences in clinical profiles and prognosis in seropositive neuromyelitis optica spectrum disorders
por: Asseyer, Susanna, et al.
Publicado: (2021)

What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients
por: Hamid, Shahd H. M., et al.
Publicado: (2017)

Area postrema syndrome: Frequency, criteria, and severity in AQP4-IgG–positive NMOSD
por: Shosha, Eslam, et al.
Publicado: (2018)

Anti-aquaporin 4 IgG Is Not Associated With Any Clinical Disease Characteristics in Neuromyelitis Optica Spectrum Disorder
por: Schmetzer, Oliver, et al.
Publicado: (2021)

Association of dengue infection with anti-alpha-gal antibodies, IgM, IgG, IgG1, and IgG2
por: Olajiga, Olayinka M., et al.
Publicado: (2022)

AQP4-IgG and MOG-IgG Related Optic Neuritis—Prevalence, Optical Coherence Tomography Findings, and Visual Outcomes: A Systematic Review and Meta-Analysis
por: Filippatou, Angeliki G., et al.
Publicado: (2020)

Pregnancy-Related Attack in Neuromyelitis Optica Spectrum Disorder With AQP4-IgG: A Single-Center Study and Meta-Analysis
por: Deng, Shuwen, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5elbptdeth744k9q175gcu217t